LT3565806T - Novel phenyl derivatives - Google Patents
Novel phenyl derivativesInfo
- Publication number
- LT3565806T LT3565806T LTEPPCT/US2018/012491T LT18012491T LT3565806T LT 3565806 T LT3565806 T LT 3565806T LT 18012491 T LT18012491 T LT 18012491T LT 3565806 T LT3565806 T LT 3565806T
- Authority
- LT
- Lithuania
- Prior art keywords
- phenyl derivatives
- novel phenyl
- novel
- derivatives
- phenyl
- Prior art date
Links
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/91—Nitro radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762443244P | 2017-01-06 | 2017-01-06 | |
US201762581355P | 2017-11-03 | 2017-11-03 | |
US201762585326P | 2017-11-13 | 2017-11-13 | |
PCT/US2018/012491 WO2018129258A1 (en) | 2017-01-06 | 2018-01-05 | Novel phenyl derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
LT3565806T true LT3565806T (en) | 2022-06-10 |
Family
ID=61569353
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEPPCT/US2018/012491T LT3565806T (en) | 2017-01-06 | 2018-01-05 | Novel phenyl derivatives |
Country Status (26)
Country | Link |
---|---|
US (4) | US10618875B2 (en) |
EP (2) | EP4086242A1 (en) |
JP (2) | JP7090088B2 (en) |
KR (1) | KR102579648B1 (en) |
CN (2) | CN110167918B (en) |
AU (1) | AU2018205811B2 (en) |
BR (1) | BR112019013371A2 (en) |
CA (1) | CA3047138C (en) |
CL (1) | CL2019001842A1 (en) |
CO (1) | CO2019006865A2 (en) |
DK (1) | DK3565806T3 (en) |
ES (1) | ES2913431T3 (en) |
GE (1) | GEP20217227B (en) |
IL (1) | IL267868B (en) |
LT (1) | LT3565806T (en) |
MX (1) | MX2019007745A (en) |
MY (1) | MY192778A (en) |
PE (1) | PE20191243A1 (en) |
PH (1) | PH12019501318A1 (en) |
PL (1) | PL3565806T3 (en) |
PT (1) | PT3565806T (en) |
SA (1) | SA519402076B1 (en) |
SI (1) | SI3565806T1 (en) |
UA (1) | UA124026C2 (en) |
WO (1) | WO2018129258A1 (en) |
ZA (1) | ZA201903808B (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10738035B2 (en) | 2015-05-13 | 2020-08-11 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
US10179792B2 (en) | 2016-03-07 | 2019-01-15 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
SI3565806T1 (en) * | 2017-01-06 | 2022-07-29 | Rivus Pharmaceuticals, Inc. | Novel phenyl derivatives |
BR112020004112A2 (en) | 2017-08-28 | 2020-09-24 | Enanta Pharmaceuticals, Inc. | hepatitis b antiviral agents |
US11058678B2 (en) | 2018-01-22 | 2021-07-13 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
UY38383A (en) | 2018-09-21 | 2020-04-30 | Enanta Pharm Inc | HETEROCYCLES FUNCTIONALIZED AS ANTIVIRAL AGENTS |
EP3883570A4 (en) | 2018-11-21 | 2022-07-13 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
US11236111B2 (en) | 2019-06-03 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
US11472808B2 (en) | 2019-06-04 | 2022-10-18 | Enanta Pharmaceuticals, Inc. | Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents |
US11760755B2 (en) | 2019-06-04 | 2023-09-19 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
US11738019B2 (en) | 2019-07-11 | 2023-08-29 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
WO2021055425A2 (en) | 2019-09-17 | 2021-03-25 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
US11802125B2 (en) | 2020-03-16 | 2023-10-31 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
EP4340829A1 (en) | 2021-05-20 | 2024-03-27 | Rivus Pharmaceuticals, Inc. | Methods of treating mitochondria-related disorders |
WO2023150759A1 (en) | 2022-02-07 | 2023-08-10 | Rivus Pharmaceuticals, Inc. | Methods of weight loss in a subject with elevated hba1c |
WO2023150767A1 (en) | 2022-02-07 | 2023-08-10 | Rivus Pharmaceuticals, Inc. | Methods of weight loss and preserving skeletal muscle mass |
WO2024112663A1 (en) | 2022-11-21 | 2024-05-30 | Rivus Pharmaceuticals, Inc. | Deuterium enriched phenyl derivatives for treating mitochondriarelated disorders or conditions |
WO2024112659A1 (en) | 2022-11-21 | 2024-05-30 | Rivus Pharmaceuticals, Inc. | Crystalline forms of 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1h-imidazole |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3828056A (en) * | 1972-09-11 | 1974-08-06 | Searle & Co | (2-(2-methyl-5-nitro-1-imidazolyl)ethyl)heteroaryloxy ethers |
EG11928A (en) * | 1974-12-16 | 1979-03-31 | Hoechst Ag | Process for preparing of 1-alkyl-2-(phenoxy-methyl)-5-nitro-imidazoles |
US5359078A (en) * | 1989-05-19 | 1994-10-25 | The United States Of America As Represented By The Department Of Health And Human Services | Signal transduction inhibitor compounds |
JP2006514101A (en) | 2002-11-08 | 2006-04-27 | ノボ・ノルデイスク・エー/エス | Safe chemical uncouplers for the treatment of obesity |
JP2007503453A (en) | 2003-05-14 | 2007-02-22 | ノボ ノルディスク アクティーゼルスカブ | Novel compounds for treating obesity |
WO2004106307A2 (en) * | 2003-05-27 | 2004-12-09 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Novel imidazole derivatives, the production thereof, and the use of the same as a medicament |
BRPI0416933A (en) | 2003-11-25 | 2007-01-16 | Novo Nordisk As | compound, pharmaceutical composition, method for treating a disease, use of a compound, and methods for increasing mitochondrial respiration in a patient, and for reducing the amount of reactive oxygen species in a patient. |
WO2005051900A1 (en) | 2003-11-25 | 2005-06-09 | Novo Nordisk A/S | Novel compounds for the treatment of obesity |
US20070010559A1 (en) | 2003-11-25 | 2007-01-11 | Novo Nordisk A/S | Indole derivatives for use as chemical uncoupler |
EP1896040B1 (en) | 2005-06-29 | 2012-08-01 | Threshold Pharmaceuticals, Inc. | Phosphoramidate alkylator prodrugs |
CA2669884A1 (en) | 2006-11-15 | 2008-05-22 | High Point Pharmaceuticals, Llc | Novel 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes |
US8022066B2 (en) | 2006-11-15 | 2011-09-20 | High Point Pharmaceuticals, Llc | 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes |
WO2008059023A1 (en) | 2006-11-15 | 2008-05-22 | High Point Pharmaceuticals, Llc | New haloalkylsulfone substituted compounds useful for treating obesity and diabetes |
US20100249161A1 (en) | 2006-11-15 | 2010-09-30 | Anders Klarskov Petersen | 2- ( 2 -hydroxyphenyl) -quinazolin-4-ones useful for treating obesity and diabetes |
WO2010048330A1 (en) | 2008-10-21 | 2010-04-29 | Threshold Pharmaceuticals, Inc. | Treatment of cancer using hypoxia activated prodrugs |
EP2179984A1 (en) * | 2008-10-27 | 2010-04-28 | Congenia S.r.l. | Acrylamido derivatives useful as inhibitors of the mitochondrial permeability transition |
CN101560189B (en) * | 2009-05-20 | 2011-02-16 | 南京大学 | Metronidazole and compound for substituting salicylic acid and preparation method and application thereof |
WO2011162633A1 (en) | 2010-06-24 | 2011-12-29 | Общество С Ограниченной Ответственностью "Mиtotex" | Soft cationic mitochondrial uncouplers |
WO2013192388A1 (en) | 2012-06-20 | 2013-12-27 | University Of Virginia Patent Foundation | Compositions and methods for regulating glucose homeostasis and insulin action |
EP3038611B1 (en) | 2013-08-30 | 2024-04-17 | Yale University | Sustained-release pharmaceutical composition comprising 2,4-dinitrophenol |
WO2015031598A2 (en) | 2013-08-30 | 2015-03-05 | Yale University | Therapeutic dnp derivatives and methods using same |
WO2016004363A2 (en) | 2014-07-03 | 2016-01-07 | NAN Global, LLC | Methods and compositions for treating obesity, preventing weight gain, promoting weight loss, promoting slimming, or treating or preventing the development of diabetes |
US20160008298A1 (en) * | 2014-07-14 | 2016-01-14 | Oregon State University | Xanthohumol-based compounds and compositions thereof, and methods of making and using the same |
EP4306167A3 (en) | 2015-01-22 | 2024-03-20 | Mitochon Pharmaceuticals, Inc. | Induced expression of brain derived neurotrophic factor (bdnf) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases |
KR102475875B1 (en) | 2016-03-07 | 2022-12-07 | 미토콘 파마슈티칼스, 인크. | Dnp and dnp prodrug treatment of neuromuscular, neurodegenerative, autoimmune, developmental, concussion, dry eye disease, and/or metabolic diseases |
SI3565806T1 (en) * | 2017-01-06 | 2022-07-29 | Rivus Pharmaceuticals, Inc. | Novel phenyl derivatives |
WO2018217757A1 (en) | 2017-05-22 | 2018-11-29 | University Of Virginia Patent Foundation | Compositions and methods for preparing and using mitochondrial uncouplers |
-
2018
- 2018-01-05 SI SI201830676T patent/SI3565806T1/en unknown
- 2018-01-05 EP EP22157494.0A patent/EP4086242A1/en active Pending
- 2018-01-05 PL PL18709129T patent/PL3565806T3/en unknown
- 2018-01-05 KR KR1020197018983A patent/KR102579648B1/en active IP Right Grant
- 2018-01-05 LT LTEPPCT/US2018/012491T patent/LT3565806T/en unknown
- 2018-01-05 ES ES18709129T patent/ES2913431T3/en active Active
- 2018-01-05 UA UAA201906673A patent/UA124026C2/en unknown
- 2018-01-05 BR BR112019013371A patent/BR112019013371A2/en active Search and Examination
- 2018-01-05 MY MYPI2019003195A patent/MY192778A/en unknown
- 2018-01-05 CN CN201880005988.7A patent/CN110167918B/en active Active
- 2018-01-05 US US16/475,390 patent/US10618875B2/en active Active
- 2018-01-05 WO PCT/US2018/012491 patent/WO2018129258A1/en unknown
- 2018-01-05 PE PE2019001339A patent/PE20191243A1/en unknown
- 2018-01-05 JP JP2019537086A patent/JP7090088B2/en active Active
- 2018-01-05 CN CN202310980210.0A patent/CN117024351A/en active Pending
- 2018-01-05 DK DK18709129.3T patent/DK3565806T3/en active
- 2018-01-05 GE GEAP201815132A patent/GEP20217227B/en unknown
- 2018-01-05 CA CA3047138A patent/CA3047138C/en active Active
- 2018-01-05 MX MX2019007745A patent/MX2019007745A/en unknown
- 2018-01-05 EP EP18709129.3A patent/EP3565806B1/en active Active
- 2018-01-05 AU AU2018205811A patent/AU2018205811B2/en active Active
- 2018-01-05 PT PT187091293T patent/PT3565806T/en unknown
-
2019
- 2019-06-11 PH PH12019501318A patent/PH12019501318A1/en unknown
- 2019-06-12 ZA ZA2019/03808A patent/ZA201903808B/en unknown
- 2019-06-27 CO CONC2019/0006865A patent/CO2019006865A2/en unknown
- 2019-07-03 CL CL2019001842A patent/CL2019001842A1/en unknown
- 2019-07-04 IL IL267868A patent/IL267868B/en unknown
- 2019-07-07 SA SA519402076A patent/SA519402076B1/en unknown
-
2020
- 2020-09-02 US US17/010,547 patent/US20200399225A1/en not_active Abandoned
-
2021
- 2021-04-15 US US17/231,168 patent/US20210238144A1/en active Pending
- 2021-10-28 US US17/513,235 patent/US20220048865A1/en not_active Abandoned
-
2022
- 2022-06-13 JP JP2022095049A patent/JP2022120118A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL267868B (en) | Novel phenyl derivatives | |
IL271607B1 (en) | New azaquinoline derivatives | |
IL272562A (en) | Novel compounds | |
GB201720187D0 (en) | Novel Compounds | |
GB201702947D0 (en) | Novel compounds | |
PL3668853T3 (en) | Novel compounds | |
GB201721729D0 (en) | Novel compounds | |
GB201721727D0 (en) | Novel compounds | |
GB201721726D0 (en) | Novel compounds | |
GB201721731D0 (en) | Novel compounds | |
GB201721732D0 (en) | Novel Compounds | |
GB201721735D0 (en) | Novel Compounds | |
GB201721736D0 (en) | Novel Compounds | |
GB201719720D0 (en) | Novel compounds | |
GB201718561D0 (en) | Novel compounds | |
GB201718563D0 (en) | Novel compounds | |
GB201718564D0 (en) | Novel compounds | |
GB201718565D0 (en) | Novel compounds | |
GB201716131D0 (en) | Novel compounds | |
GB201714699D0 (en) | Novel compounds | |
GB201713079D0 (en) | Novel Compounds | |
GB201713082D0 (en) | Novel compounds | |
GB201713076D0 (en) | Novel compounds | |
GB201713085D0 (en) | Novel compounds | |
GB201713083D0 (en) | Novel compounds |